RxDoctor Payments Data

Samuel Mathew, MD

Cardiovascular Disease · Orland Park, ILNPI 1801959705

Payments from drug & device makers

$1,110in general payments, 2019–2025

Across 74 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$350
  • AbbVie$215
  • Novartis$160
  • Esperion Therapeutics, Inc.$103
  • Ardelyx, Inc.$65
  • Amarin Pharma, Inc.$51
  • plus $166 from 5 others

What the payments were for

  • Food & beverage$1,110100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,110 in reported general payments places this provider in the 40th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$99,749
Medicare patients
40
Services billed
2,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$101,981
Combivent RespimatIpratropium/Albuterol Sulfate101$49,495
LinzessLinaclotide88$48,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$39,315
EntrestoSacubitril/Valsartan39$26,297
Janumet XrSitagliptin Phos/Metformin Hcl32$25,026
EliquisApixaban29$18,987
Breo ElliptaFluticasone/Vilanterol45$17,687
FarxigaDapagliflozin Propanediol18$15,742
VascepaIcosapent Ethyl48$14,915
JardianceEmpagliflozin13$11,421
JanuviaSitagliptin Phosphate15$11,221
Diclofenac Sodium83$7,661
Dexlansoprazole DrDexlansoprazole37$7,164
CreonLipase/Protease/Amylase11$5,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Synthroid$215$54,531112 claims
NovartisEntresto$160$26,29739 claims
AstraZenecaFarxiga$350$15,74218 claims
Arbor Pharmaceuticals, Inc.Edarbi$50$3,11513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →